|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Chinese University of Hong Kong |
| Information provided by: | Chinese University of Hong Kong |
| ClinicalTrials.gov Identifier: | NCT00404443 |
Purpose
To study the efficacy of acupuncture used as an adjunct measure for patients with refractory RA
| Condition | Intervention | Phase |
|
Rheumatoid Arthritis |
Device: Acupuncture |
Phase II |
| MedlinePlus related topics: | Acupuncture Rheumatoid Arthritis |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Efficacy of Traditional Chinese Acupuncture in the Treatment of Rheumatoid Arthritis: a Double-Blind Controlled Pilot Study |
| Enrollment: | 36 |
| Study Start Date: | December 2004 |
| Study Completion Date: | January 2006 |
| Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|
1: Sham Comparator
arm 1: placebo needle
|
Device: Acupuncture
Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
|
The study employs a randomized, prospective, double-blind, placebo-controlled trial to evaluate the effect of electroacupuncture, traditional Chinese acupuncture and sham acupuncture in patients with refractory RA. All patients received 20 sessions over a period of 10 weeks. Six acupuncture points were chosen. Primary outcome is the changes in the pain score. Secondary outcomes included the changes in the ACR core disease measures, DAS 28 score and the number of patients who achieved ACR 20 at week 10.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | The Chinese University of Hong Kong ( Lai-Shan Tam ) |
| Study ID Numbers: | TCM04001 |
| First Received: | November 27, 2006 |
| Last Updated: | May 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00404443 |
| Health Authority: | Hong Kong: Department of Health |
|
|
|
|